Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

A group of drug wholesalers, retailers, health plans and others have asked a U.S. appeals court to revive their lawsuits accusing pharmaceutical company Ranbaxy of conspiring with Pfizer to delay the ...

The study theorized that Canada has had a more cooperative relationship between drug manufacturers, government agencies, ...

Elizabeth Warren seeks scrutiny of deals that would allow drug middlemen McKesson, Cardinal Health, and Cencora to also ...

Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies ...

The higher-dose version of the eye disease drug was launched in August 2023 and allows for longer intervals between ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to ...

Eli Lilly and Co. lowered its full-year guidance Wednesday on lackluster sales of its blockbuster weight-loss drug, a shocking miss for a drugmaker that had been going from strength to strength on ...

One of the president’s signature policies was spurred by personal tragedy.

Eli Lilly shares slid in premarket trading after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inven ...